Takeo Ohsugi Selected Research

Therapeutics

1/2023	The unique activity of saponin: Induction of cytotoxicity in HTLV-1 infected cells.
11/2007	Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
10/2005	Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takeo Ohsugi Research Topics

Disease

11	Neoplasms (Cancer) 12/2023 - 08/2005
11	T-Cell Leukemia (Leukemia, T Cell) 01/2022 - 10/2005
6	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 12/2023 - 08/2005
4	Infections 01/2022 - 01/2008
4	Carcinogenesis 08/2018 - 01/2006
3	Lymphoma (Lymphomas) 11/2019 - 09/2009
2	Breast Neoplasms (Breast Cancer) 01/2022 - 11/2012
2	Leukemia 08/2018 - 01/2013
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2023
1	Communicable Diseases (Infectious Diseases) 01/2023
1	Multiple Myeloma 01/2022
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2020
1	Hypothermia 06/2019
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2018
1	Disease Progression 09/2013
1	Joint Diseases (Joint Disease) 04/2011
1	Rheumatoid Arthritis 04/2011
1	Arthritis (Polyarthritis) 04/2011
1	Primary Effusion Lymphoma 09/2009
1	Ascites 09/2009
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 08/2005

Drug/Important Bio-Agent (IBA)

6	NF-kappa B (NF-kB)IBA 09/2009 - 08/2005
2	AMP-Activated Protein KinasesIBA 12/2023 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2019
2	CaspasesIBA 12/2019 - 08/2018
2	Sirtuin 2IBA 01/2019 - 08/2018
2	NAD (NADH)IBA 01/2019 - 08/2018
2	SirtuinsIBA 01/2019 - 08/2018
2	Oncogene Proteins (Oncogene Protein)IBA 05/2017 - 09/2013
2	Antiviral Agents (Antivirals)IBA 12/2008 - 01/2007
2	dehydroxymethylepoxyquinomicinIBA 11/2007 - 08/2005
1	acadesineIBA 12/2023
1	AICA ribonucleotide (ZMP)IBA 12/2023
1	N1- (4- (3- isopropyl- 2- methylindazol- 5- yl)pyrimidin- 2- yl)- N4- tetrahydropyran- 4- yl- cyclohexane- 1,4- diamineIBA 01/2023
1	SRT1720IBA 01/2022
1	Sirtuin 1IBA 01/2022
1	dorsomorphinIBA 01/2020
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020
1	Histones (Histone)IBA 11/2019
1	ChromatinIBA 11/2019
1	Phytic Acid (Inositol Hexaphosphate)IBA 11/2019
1	ProdrugsIBA 11/2019
1	alphaxalone (alfaxalone)IBA 06/2019
1	Protein Isoforms (Isoforms)IBA 01/2019
1	Lymphocyte Specific Protein Tyrosine Kinase p56(lck) (p56 lck)IBA 01/2013
1	Hormones (Hormone)IBA 11/2012
1	K-18 conjugate (K18)IBA 11/2012
1	Estrogens (Estrogen)FDA Link 11/2012
1	Tamoxifen FDA LinkGeneric 11/2012
1	Rheumatoid FactorIBA 04/2011
1	CollagenIBA 04/2011
1	Collagen Type II (Type II Collagen)IBA 04/2011
1	Viral ProteinsIBA 12/2009
1	cepharanthineIBA 09/2009
1	AlkaloidsIBA 09/2009
1	Retroelements (Retrotransposon)IBA 12/2008
1	tax Gene Products (tax Gene Product)IBA 05/2007
1	Cytidine DeaminaseIBA 01/2007
1	NucleotidesIBA 02/2006
1	Messenger RNA (mRNA)IBA 02/2006
1	Transcription Factors (Transcription Factor)IBA 08/2005

Therapy/Procedure

3	Therapeutics 01/2023 - 10/2005
1	Blood Transfusion (Blood Transfusions) 01/2022
1	Transplantation 11/2012
1	Intraperitoneal Injections 09/2009
1	Chemoprevention 10/2005
1	Drug Therapy (Chemotherapy) 10/2005